Voyager Therapeutics, Inc.(VYGR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,934 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in VYGR
Events flagged as statistical outliers against VYGR's own multi-year baseline — not fixed dollar thresholds.
VYGR Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Voyager Therapeutics, Inc. (VYGR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VYGR at 8.1/100 on a 32-signal composite quality model, placing it at rank #2,934 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (2.9) and free cash flow (3.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Voyager Therapeutics, Inc. reports quarterly revenue of $3.2M, net income of $-24.5M, free cash flow of $-25.8M. Top institutional holders of VYGR by reported 13-F value include BlackRock, MILLENNIUM MANAGEMENT, ARMISTICE CAPITAL, based on the most recent SEC filings. VYGR trades on the Nasdaq exchange and files with the SEC under CIK 1640266. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VYGR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Voyager Therapeutics, Inc. directly from SEC EDGAR. Voyager Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 6 and 79 since 2021, currently 8.1 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$3.2M
Net Income
Q2 2026
$-24.5M
Free Cash Flow
Q2 2026
$-25.8M
ROIC
Q2 2026
-68.4%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-49.5% YoYNet Income
-84.2% YoYOperating Income
-58.3% YoYEPS (Diluted)
-80.5% YoYTotal Assets
-35.8% YoYOp. Cash Flow
-765.2% YoYFree Cash Flow
-617.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $40.4M -49.5% | $80.0M -68.0% | $250.0M +511.2% | $40.9M +9.3% | $37.4M -78.1% | $171.1M |
| Net Income | $-119.7M -84.2% | $-65.0M -149.1% | $132.3M +385.1% | $-46.4M +34.8% | $-71.2M -293.8% | $36.7M |
| Operating Income | $-131.8M -58.3% | $-83.3M -168.3% | $122.0M +340.0% | $-50.8M +30.9% | $-73.6M -368.8% | $27.4M |
| EPS (Diluted) | $-2.04 -80.5% | $-1.13 -138.0% | $2.97 +345.5% | $-1.21 +36.0% | $-1.89 -292.9% | $0.98 |
| Total Assets | $252.3M -35.8% | $393.1M +11.9% | $351.3M +120.4% | $159.4M -17.8% | $193.9M -25.9% | $261.6M |
| Operating Cash Flow | $-132.5M -765.2% | $-15.3M -119.6% | $77.9M +722.9% | $-12.5M +76.6% | $-53.5M +44.7% | $-96.7M |
| Free Cash Flow | $-135.1M -617.2% | $-18.8M -125.2% | $74.7M +597.8% | $-15.0M +72.8% | $-55.1M +49.3% | $-108.8M |
Get alerted when VYGR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Voyager Therapeutics, Inc. including:
Top Institutional Holders of VYGR
BlackRock, Inc.
$18.1M5,172,063 shMILLENNIUM MANAGEMENT LLC
$15.6M4,442,951 shARMISTICE CAPITAL, LLC
$12.0M3,436,000 shVestal Point Capital, LP
$9.2M2,625,000 shVANGUARD CAPITAL MANAGEMENT LLC
$8.2M2,345,674 shGEODE CAPITAL MANAGEMENT, LLC
$4.7M1,330,492 shOpaleye Management Inc.
$4.1M1,185,000 shSTATE STREET CORP
$3.8M1,076,422 shTWO SIGMA INVESTMENTS, LP
$3.3M948,517 shDIMENSIONAL FUND ADVISORS LP
$2.9M838,184 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $18.1M | 5,172,063 |
| MILLENNIUM MANAGEMENT LLC | $15.6M | 4,442,951 |
| ARMISTICE CAPITAL, LLC | $12.0M | 3,436,000 |
| Vestal Point Capital, LP | $9.2M | 2,625,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.2M | 2,345,674 |
| GEODE CAPITAL MANAGEMENT, LLC | $4.7M | 1,330,492 |
| Opaleye Management Inc. | $4.1M | 1,185,000 |
| STATE STREET CORP | $3.8M | 1,076,422 |
| TWO SIGMA INVESTMENTS, LP | $3.3M | 948,517 |
| DIMENSIONAL FUND ADVISORS LP | $2.9M | 838,184 |
Companies Similar to VYGR
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Taysha Gene Therapies, Inc.
Silence Therapeutics plc
Monte Rosa Therapeutics, Inc.
uniQure N.V.
Wave Life Sciences, Inc.
Nurix Therapeutics, Inc.
Stoke Therapeutics, Inc.
Avalo Therapeutics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put VYGR on your watchlist
Track score changes the day Voyager Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is VYGR a good stock to buy?
13F Pro's AI-powered analysis of Voyager Therapeutics, Inc. (VYGR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VYGR are available on the VYGR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VYGR is classified as a small company.
Which hedge funds own VYGR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VYGR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Voyager Therapeutics, Inc.'s investment landscape.